Independent Review into Mental Health Conditions, ADHD and Autism On 9 October 2026, the Department of Health and Social Care (DHSC) published the Independent review into prevalence and support for mental health conditions, ADHD and autism, chaired by Professor Peter Fonagy.1 The review was commissioned in response to a rapid rise in referrals and diagnoses, […]
NICE published final draft guidance on 3 September 2026 recommending mirdametinib (Ezmekly®) for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas in children and young people aged 2–17 years who require systemic therapy.1 Mirdametinib is a MEK inhibitor indicated where tumours are not amenable to surgery. The eligible population in England is approximately 200 […]
On 6 August 2026, NICE recommended acalabrutinib (Calquence®, AstraZeneca) in two combination regimens for first-line treatment of blood cancers. Acalabrutinib plus bendamustine and rituximab was recommended for adults with untreated mantle cell lymphoma (MCL) not eligible for autologous stem cell transplant, with approximately 350 patients expected to benefit. Acalabrutinib plus venetoclax (without obinutuzumab) was recommended […]
Unit A5, Endeavour Business Park
Penner Road, Havant
PO9 1QN
Company Registration Number: 5334133
Company VAT Number: 855 7246 95
© 2026 Blueteq Ltd
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.